Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationType 2 DiabetesIssue 611

FDA Approves Eli Lilly Diabetes Combo Drug Jentadueto

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the FDA approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets....

Advertisement

Drawing from the momentum of Tradjenta™ (linagliptin) tablets -- approved for U.S. marketing in May 2011 – JENTADUETO combines linagliptin and metformin into a new, single-tablet option, taken twice daily and comes in 3 different dosages.

JENTADUETO is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate. JENTADUETO is not for the treatment of type 1 diabetes or diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin.

At the maximum dose, JENTADUETO demonstrated placebo-corrected reductions in hemoglobin A1Clevels of up to 1.7 percent. It can be used alone or in combination with a sulfonylurea, another commonly prescribed medication for type 2 diabetes.

The JENTADUETO label contains a boxed warning because the addition of metformin which may cause a rare but serious condition called lactic acidosis (a build-up of lactic acid in the blood) that can cause death. It is not for treatment of type 1 diabetes or diabetic ketoacidosis and has not been studied in combination with insulin. The dosage should be individualized based on the patient's current regimen and the maximum recommended dose is 2.5 mg linagliptin/1000 mg metformin twice a day. It should be given twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.

It comes in 3 dosage forms, 2.5 mg linagliptin/500 mg metformin hydrochloride, 2.5 mg linagliptin/850 mg metformin hydrochloride and 2.5 mg linagliptin/1000 mg metformin hydrochloride.

Contraindications include: renal impairment, metabolic acidosis and hypersensitivity to linagliptin or metformin.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company news release

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 01 February, 2012 and appeared in  MedicationType 2 DiabetesIssue 611

Past five issues: Diabetes Clinical Mastery Series Issue 237 | Issue 777 | Diabetes Clinical Mastery Series Issue 236 | Issue 776 | Diabetes Clinical Mastery Series Issue 235 |

2015 Most Popular Articles:

Glyburide Used for Gestational Diabetes May Increase Risk of Birth Complications
Posted April 02, 2015
A Potential New Type 2 Diabetes Indicator
Posted April 02, 2015
A Third Treatment Option in Uncontrolled Type 2 Diabetes
Posted April 02, 2015
Women Retain Insulin Sensitivity Better than Men
Posted April 02, 2015
Gastric Electrical Stimulation an Alternative to Insulin Injections?
Posted April 02, 2015
A Novel Scale May Indicate Glycemic Progression to Type 1 Diabetes
Posted April 02, 2015
Artificial Pancreas Software Algorithm Receives Approval in Europe
Posted April 02, 2015
HbA1c and OGTT Performance in Prediabetic Obese Adolescents
Posted April 02, 2015
Glycemic Control and Medications in T2DM Elderly with Dementia
Posted April 02, 2015
Type 2 Diabetes and Other Diseases Risk Related to Increase in Artificial Light?
Posted April 02, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Will you stop recommending the DPP-4s for your patients?
CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology



Search Articles On Diabetes In Control